CoChat

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled ‘dark state’.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-08115-8

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Src phosphorylation of KRAS alters the structure of the switch regions. a HEK293 cells transfected with the indicated plasmids were lysed, treated with (+) or without (−) calf intestinal alkaline phosphatase (CIP), immunoprecipitated, and immunoblotted with the indicated antibodies. b Purified recombinant human GDP- and GTP-bound KRAS protein were subjected to in vitro kinase assay using purified recombinant Srccat kinase and were immunoprecipitated and immunoblotted with the indicated antibodies. c An overlay of 2D 1H-15N HSQC spectra of unmodified KRAS-GDP (red) and pKRAS-GDP phosphorylated by Src (black). The labeled residues are residues with notable chemical shift perturbation. d Histogram mapping the backbone NH chemical shift changes caused by Src phosphorylation. Chemical shift changes of the N and NH peaks of the unmodified vs. phosphorylated cross-peaks in the 2D 1H-15N HSQC spectra were calculated using the formula ∆δ NH.N(ppm) = √(〖 (∆H)〗^2 + 〖(∆N/5)〗^2) and plotted against residue number. e Overlay of 1H-15N HSQC spectra of 15N-KRAS tyrosine peaks before (red) and after (black) phosphorylation. The residue numbers are indicated in blue and the arrows indicate the direction of the chemical shift change. Full spectra are shown in c. f Chemical shift changes of the KRAS tyrosine residues induced by phosphorylation. g Upper panel: Mass spectra of unmodified GDP-loaded KRAS (left) and KRAS loaded with the non-hydrolyzable GTP analog GMPPNP (right). The major peak of KRAS is shaded green, and the higher molecular weight peaks (+22 Da) correspond to sodium adducts (the predicted molecular mass of 15N-KRAS (residues 1–173 C118S) is 20074.35 Da). Lower panel: Mass spectrum of GDP-loaded pKRAS (left) and GTP-loaded pKRAS (right) following treatment with Src in vitro. The three peaks highlighted in green correspond to unmodified KRAS, KRAS phosphorylated at one site (+80 Da) and KRAS phosphorylated at two sites (+160 Da). The immunoblot data are representative of at least three independent experiments
Fig. 1 Src phosphorylation of KRAS alters the structure of the switch regions. a HEK293 cells transfected with the indicated plasmids were lysed, treated with (+) or without (−) calf intestinal alkaline phosphatase (CIP), immunoprecipitated, and immunoblotted with the indicated antibodies. b Purified recombinant human GDP- and GTP-bound KRAS protein were subjected to in vitro kinase assay using purified recombinant Srccat kinase and were immunoprecipitated and immunoblotted with the indicated antibodies. c An overlay of 2D 1H-15N HSQC spectra of unmodified KRAS-GDP (red) and pKRAS-GDP phosphorylated by Src (black). The labeled residues are residues with notable chemical shift perturbation. d Histogram mapping the backbone NH chemical shift changes caused by Src phosphorylation. Chemical shift changes of the N and NH peaks of the unmodified vs. phosphorylated cross-peaks in the 2D 1H-15N HSQC spectra were calculated using the formula ∆δ NH.N(ppm) = √(〖 (∆H)〗^2 + 〖(∆N/5)〗^2) and plotted against residue number. e Overlay of 1H-15N HSQC spectra of 15N-KRAS tyrosine peaks before (red) and after (black) phosphorylation. The residue numbers are indicated in blue and the arrows indicate the direction of the chemical shift change. Full spectra are shown in c. f Chemical shift changes of the KRAS tyrosine residues induced by phosphorylation. g Upper panel: Mass spectra of unmodified GDP-loaded KRAS (left) and KRAS loaded with the non-hydrolyzable GTP analog GMPPNP (right). The major peak of KRAS is shaded green, and the higher molecular weight peaks (+22 Da) correspond to sodium adducts (the predicted molecular mass of 15N-KRAS (residues 1–173 C118S) is 20074.35 Da). Lower panel: Mass spectrum of GDP-loaded pKRAS (left) and GTP-loaded pKRAS (right) following treatment with Src in vitro. The three peaks highlighted in green correspond to unmodified KRAS, KRAS phosphorylated at one site (+80 Da) and KRAS phosphorylated at two sites (+160 Da). The immunoblot data are representative of at least three independent experimentsCC BY · PubMed Central
Fig. 2 Src phosphorylates KRAS tyrosine 32 and 64. a–c Two phosphorylated tyrosine residues from the KRAS protein sequence (a) were identified from in vitro kinase reaction samples that were reduced/alkylated, trypsin-digested, and analyzed by LC-MS. MS/MS spectra matched indicated KRAS tryptic peptides containing residue Y32 (b) and Y64 (c). d Upper panel: Mass spectra of unmodified KRASY32F (left) and KRASY64F (right). Lower panel: Mass spectrum of pKRASY32F (left) and pKRASY64F (right). The major peak of KRAS is shaded light green. e HEK293 cells were transfected with the indicated plasmids. Cells were lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three separate experiments. f GTP-bound KRAS were subjected to in vitro kinase assay using purified Src kinase (left lane) and were separated into un-phosphorylated (KRAS), mono-phosphorylated (KRAS.PO3), and di-phosphorylated (KRAS.2PO3) forms by anion exchange chromatography. These samples were then analyzed by 50 μM Mn2+-PhosTag SDS-PAGE (upper panel) or conventional SDS-PAGE (lower panel) and immunoblotted with anti-RAS antibody. Asterisk indicates non-specific band. IP immunoprecipitation, WCE whole-cell extract. The immunoblot data are representative of at least three independent experiments
Fig. 2 Src phosphorylates KRAS tyrosine 32 and 64. a–c Two phosphorylated tyrosine residues from the KRAS protein sequence (a) were identified from in vitro kinase reaction samples that were reduced/alkylated, trypsin-digested, and analyzed by LC-MS. MS/MS spectra matched indicated KRAS tryptic peptides containing residue Y32 (b) and Y64 (c). d Upper panel: Mass spectra of unmodified KRASY32F (left) and KRASY64F (right). Lower panel: Mass spectrum of pKRASY32F (left) and pKRASY64F (right). The major peak of KRAS is shaded light green. e HEK293 cells were transfected with the indicated plasmids. Cells were lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three separate experiments. f GTP-bound KRAS were subjected to in vitro kinase assay using purified Src kinase (left lane) and were separated into un-phosphorylated (KRAS), mono-phosphorylated (KRAS.PO3), and di-phosphorylated (KRAS.2PO3) forms by anion exchange chromatography. These samples were then analyzed by 50 μM Mn2+-PhosTag SDS-PAGE (upper panel) or conventional SDS-PAGE (lower panel) and immunoblotted with anti-RAS antibody. Asterisk indicates non-specific band. IP immunoprecipitation, WCE whole-cell extract. The immunoblot data are representative of at least three independent experimentsCC BY · PubMed Central
Fig. 3 SHP2 dephosphorylates tyrosyl phosphorylated KRAS. a, b HEK293 cells were transfected with the indicated plasmids. Cells were lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. c Phosphorylation was initiated by addition of 2 μM of Src to 250 μM of KRAS in the presence of 2 mM ATP and 1 mM activated sodium vanadate. Sequential 1H-15N HSQC NMR spectra were collected, and peaks from un-phosphorylated and phosphorylated Tyr32 (blue) and Tyr64 (red) were integrated from each spectrum to plot curves of the fraction phosphorylated vs. time for each site. The error bars correspond to the noise-to-signal ratio of the respective peaks. The relative rates of phosphorylation of each site determined from a representative experiment (performed in duplicate) by curve fitting are shown in histograms on the right. The error bars indicate the standard curve fitting error obtained from the fitting analysis. d SHP2 (2 μM) was added to Src-phosphorylated KRAS sample purified in the presence of vanadate, and sequential 1H-15N NMR spectra were collected to monitor dephosphorylation. Similar to c, the fractions of phosphorylated Tyr32 (blue) and Tyr64 (red) were plotted and rates of dephosphorylation were determined and are shown in the histograms. Rate curves from a representative experiment (performed in duplicate) were fitted to one phase exponential decay/association functions using the GraphPad Prism 4.0 software. Histogram error bars indicate the standard curve fitting error obtained from the fitting analysis. e Top panel; experimental set-up whereby two tubes containing 200 μM of KRAS and 3 μM of Src were incubated in in the presence of 2 mM ATP for 2 h (in the absence of vanadate). Sample 1 was then snap frozen and stored at −80 °C for MS analysis, and 3 μM of SHP2 was added to the remaining tube and incubated for an additional 2 h. Sample 2 was then frozen. Bottom panels; MS spectra of samples 1 and 2 with phosphorylation state of each mass indicated. f HEK293 cells transfected with the indicated plasmids were treated with (+) or without (−) 10 μM of 11a-1, lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three independent experiments
Fig. 3 SHP2 dephosphorylates tyrosyl phosphorylated KRAS. a, b HEK293 cells were transfected with the indicated plasmids. Cells were lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. c Phosphorylation was initiated by addition of 2 μM of Src to 250 μM of KRAS in the presence of 2 mM ATP and 1 mM activated sodium vanadate. Sequential 1H-15N HSQC NMR spectra were collected, and peaks from un-phosphorylated and phosphorylated Tyr32 (blue) and Tyr64 (red) were integrated from each spectrum to plot curves of the fraction phosphorylated vs. time for each site. The error bars correspond to the noise-to-signal ratio of the respective peaks. The relative rates of phosphorylation of each site determined from a representative experiment (performed in duplicate) by curve fitting are shown in histograms on the right. The error bars indicate the standard curve fitting error obtained from the fitting analysis. d SHP2 (2 μM) was added to Src-phosphorylated KRAS sample purified in the presence of vanadate, and sequential 1H-15N NMR spectra were collected to monitor dephosphorylation. Similar to c, the fractions of phosphorylated Tyr32 (blue) and Tyr64 (red) were plotted and rates of dephosphorylation were determined and are shown in the histograms. Rate curves from a representative experiment (performed in duplicate) were fitted to one phase exponential decay/association functions using the GraphPad Prism 4.0 software. Histogram error bars indicate the standard curve fitting error obtained from the fitting analysis. e Top panel; experimental set-up whereby two tubes containing 200 μM of KRAS and 3 μM of Src were incubated in in the presence of 2 mM ATP for 2 h (in the absence of vanadate). Sample 1 was then snap frozen and stored at −80 °C for MS analysis, and 3 μM of SHP2 was added to the remaining tube and incubated for an additional 2 h. Sample 2 was then frozen. Bottom panels; MS spectra of samples 1 and 2 with phosphorylation state of each mass indicated. f HEK293 cells transfected with the indicated plasmids were treated with (+) or without (−) 10 μM of 11a-1, lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least three independent experimentsCC BY · PubMed Central
Fig. 4 Endogenous RAS phosphorylation is regulated temporally by Src and SHP2. a WT, Src/Yes/Fyn (SYF)−/− and CRISPR/Cas9-mediated SHP2−/− MEFs were serum starved and treated with 20 ng/ml of PDGF-BB. Equal amounts of lysates were immunoprecipitated with isotype-matched antibody or anti-pTyr antibody and immunoblotted with the indicated antibodies. b SYF−/− and SHP2−/− MEFs were serum starved and treated with 20 ng/ml of PDGF-BB. Equal amounts of lysates were immunoprecipitated with isotype matched antibody or anti-RAS antibody and immunoblotted with the indicated antibodies. c MEFs were serum starved and treated with 20 ng/ml of PDGF-BB or were left untreated for the indicated periods of time. Equal amounts of lysates were immunoprecipitated with isotype-matched antibody or anti-pTyr antibody and immunoblotted with the indicated antibodies. d SYF−/− and SHP2−/− MEF lysates were immunoprecipitated with isotype-matched antibody or anti-RAS antibody and analyzed by 50 μM Mn2+-PhosTag SDS-PAGE. Asterisk indicates non-specific band. e CRISPR/Cas9-mediated non-target (Ctrl) or SHP2−/− CFPAC1 cells were serum starved and treated with (+) or without (−) 10 ng/ml of EGF. Equal amounts of lysates were immunoprecipitated and immunoblotted with the indicated antibodies. f OCIP.343 xenograft tumor lysates from the indicated treatment groups were immunoprecipitated with isotype-matched antibody or anti-RAS antibody and analyzed by Mn2+-PhosTag SDS-PAGE. Arrow indicates a slower migrating band. The immunoblot data are representative of at least three independent experiments
Fig. 4 Endogenous RAS phosphorylation is regulated temporally by Src and SHP2. a WT, Src/Yes/Fyn (SYF)−/− and CRISPR/Cas9-mediated SHP2−/− MEFs were serum starved and treated with 20 ng/ml of PDGF-BB. Equal amounts of lysates were immunoprecipitated with isotype-matched antibody or anti-pTyr antibody and immunoblotted with the indicated antibodies. b SYF−/− and SHP2−/− MEFs were serum starved and treated with 20 ng/ml of PDGF-BB. Equal amounts of lysates were immunoprecipitated with isotype matched antibody or anti-RAS antibody and immunoblotted with the indicated antibodies. c MEFs were serum starved and treated with 20 ng/ml of PDGF-BB or were left untreated for the indicated periods of time. Equal amounts of lysates were immunoprecipitated with isotype-matched antibody or anti-pTyr antibody and immunoblotted with the indicated antibodies. d SYF−/− and SHP2−/− MEF lysates were immunoprecipitated with isotype-matched antibody or anti-RAS antibody and analyzed by 50 μM Mn2+-PhosTag SDS-PAGE. Asterisk indicates non-specific band. e CRISPR/Cas9-mediated non-target (Ctrl) or SHP2−/− CFPAC1 cells were serum starved and treated with (+) or without (−) 10 ng/ml of EGF. Equal amounts of lysates were immunoprecipitated and immunoblotted with the indicated antibodies. f OCIP.343 xenograft tumor lysates from the indicated treatment groups were immunoprecipitated with isotype-matched antibody or anti-RAS antibody and analyzed by Mn2+-PhosTag SDS-PAGE. Arrow indicates a slower migrating band. The immunoblot data are representative of at least three independent experimentsCC BY · PubMed Central
Fig. 5 Tyrosyl phosphorylation of KRAS disrupts GTPase cycle. a Overlay of four 1H-15N HSQC spectra of two representative residues T74 and M67, in which the four peaks represent GDP-loaded KRAS (black), GTP-loaded KRAS (blue), GDP-loaded Src-phosphorylated (p)KRAS (red), and GTP-loaded pKRAS (green). b Real-time NMR-derived nucleotide exchange curves for unmodified vs. Src-phosphorylated KRAS. A 250μM sample of GDP-loaded 15N KRAS (black) or pKRAS (blue) was incubated with ten-fold molar excess of GTPγS. Each dot represents mean fraction of KRAS that is loaded with GDP on the basis of peak intensities [IGDP/(IGDP + IGTPɣS)] from the same three residues of KRAS and pKRAS. SOScat was added at a ratio of 1:600 to KRAS (orange) or pKRAS (red). c Src phosphorylation of KRAS impairs SOScat-assisted nucleotide exchange. Fold increase in the rate of exchange upon addition of SOScat to KRAS or pKRAS. The reaction was performed twice in the absence and twice in the presence of SOScat and four ratios were determined from each pairwise comparison. d GTP hydrolysis curves illustrating intrinsic and RASA1 GAP domain (1:3000 ratio) assisted GTP hydrolysis for unmodified KRAS and pKRAS. e Src phosphorylation of KRAS reduces sensitivity to GAP activity. Fold increase in the rate of GTP hydrolysis with addition of RASA1 GAP domain for KRAS vs. pKRAS. The reaction was performed twice in the absence and twice in the presence of RASA1 GAP domain and four ratios were determined from each pairwise comparison. b, d present a single representative experiment that was repeated at least twice. Error bars represent the standard deviation of the fraction GDP as reported by three pairs of cross-peaks. Error bars in c, e indicate standard deviation of the fold changes
Fig. 5 Tyrosyl phosphorylation of KRAS disrupts GTPase cycle. a Overlay of four 1H-15N HSQC spectra of two representative residues T74 and M67, in which the four peaks represent GDP-loaded KRAS (black), GTP-loaded KRAS (blue), GDP-loaded Src-phosphorylated (p)KRAS (red), and GTP-loaded pKRAS (green). b Real-time NMR-derived nucleotide exchange curves for unmodified vs. Src-phosphorylated KRAS. A 250μM sample of GDP-loaded 15N KRAS (black) or pKRAS (blue) was incubated with ten-fold molar excess of GTPγS. Each dot represents mean fraction of KRAS that is loaded with GDP on the basis of peak intensities [IGDP/(IGDP + IGTPɣS)] from the same three residues of KRAS and pKRAS. SOScat was added at a ratio of 1:600 to KRAS (orange) or pKRAS (red). c Src phosphorylation of KRAS impairs SOScat-assisted nucleotide exchange. Fold increase in the rate of exchange upon addition of SOScat to KRAS or pKRAS. The reaction was performed twice in the absence and twice in the presence of SOScat and four ratios were determined from each pairwise comparison. d GTP hydrolysis curves illustrating intrinsic and RASA1 GAP domain (1:3000 ratio) assisted GTP hydrolysis for unmodified KRAS and pKRAS. e Src phosphorylation of KRAS reduces sensitivity to GAP activity. Fold increase in the rate of GTP hydrolysis with addition of RASA1 GAP domain for KRAS vs. pKRAS. The reaction was performed twice in the absence and twice in the presence of RASA1 GAP domain and four ratios were determined from each pairwise comparison. b, d present a single representative experiment that was repeated at least twice. Error bars represent the standard deviation of the fraction GDP as reported by three pairs of cross-peaks. Error bars in c, e indicate standard deviation of the fold changesCC BY · PubMed Central
Fig. 6 Tyrosyl phosphorylation of KRAS attenuates binding to RAF. a Purified recombinant human GTP-bound KRAS protein was subjected to in vitro kinase assay using purified recombinant Src kinase and pulled down using Raf-1:RBD-conjugated beads or immunoprecipitated and immunoblotted with the indicated antibodies. b The binding of un-, mono-, and di-phosphorylated KRAS, each at a concentration of 250 nM, to immobilized GST-BRAF-RBD was measured using biolayer interferometry (Octet). The full binding curves at a range of KRAS concentrations is shown in Supplementary Fig. 8. Left panel: wild-type KRAS. Right panel: KRASG12V mutant. c, d HEK293 cells were transfected with the indicated plasmids. Cells were lysed, pulled down using Raf-1:RBD-conjugated beads, or were immunoprecipitated and immunoblotted with the indicated antibodies. Numerical values indicate the ratio of quantified signals over the control (lane 1 of each panel; set at 1.0) determined by densitometry using the ImageJ software. The immunoblot data are representative of at least three independent experiments. PD pulldown
Fig. 6 Tyrosyl phosphorylation of KRAS attenuates binding to RAF. a Purified recombinant human GTP-bound KRAS protein was subjected to in vitro kinase assay using purified recombinant Src kinase and pulled down using Raf-1:RBD-conjugated beads or immunoprecipitated and immunoblotted with the indicated antibodies. b The binding of un-, mono-, and di-phosphorylated KRAS, each at a concentration of 250 nM, to immobilized GST-BRAF-RBD was measured using biolayer interferometry (Octet). The full binding curves at a range of KRAS concentrations is shown in Supplementary Fig. 8. Left panel: wild-type KRAS. Right panel: KRASG12V mutant. c, d HEK293 cells were transfected with the indicated plasmids. Cells were lysed, pulled down using Raf-1:RBD-conjugated beads, or were immunoprecipitated and immunoblotted with the indicated antibodies. Numerical values indicate the ratio of quantified signals over the control (lane 1 of each panel; set at 1.0) determined by densitometry using the ImageJ software. The immunoblot data are representative of at least three independent experiments. PD pulldownCC BY · PubMed Central
Fig. 7 Model of the impact of phosphorylation on KRAS GTPase cycle and structural rationale. a Phosphorylation decouples KRAS from effectors and GTPase cycle regulation. The GTPase cycle of unmodified KRAS is shown on top. Nucleotide exchange and hydrolysis are accelerated by the activities of GEFs and GAPs, respectively. GTP-loaded KRAS binds and activates RAF. Src phosphorylation of Tyr32 and Tyr64 of KRAS-GDP or KRAS-GTP alters all steps in this GTPase cycle (lower part). Upon phosphorylation, KRAS becomes insensitive to regulation by both GEFs and GAPs, whereas intrinsic nucleotide exchange is enhanced and intrinsic GTP hydrolysis is impaired. This leads to the accumulation of phosphorylated KRAS-GTP, which has reduced affinity for RAF, thus phosphorylation limits KRAS signaling. SHP2 dephosphorylates KRAS and thereby unleashes KRAS-GTP to rapidly activate RAF. Inhibition of SHP2 promotes accumulation of phosphorylated KRAS, dampening RAF signaling and subsequently suppressing oncogenesis. Line thickness and number of arrowheads represent relative reaction rates of each step. b Ribbon diagram SOS (green) contact with Tyr32 and Tyr64 of RAS (PDB ID 1BKD). c Proposed coordination of switch I and switch II RAS residues in intrinsic GTP hydrolysis (PDB ID 4G0N). d Switch I and II (blue) of RAS are the main interaction site with GAP (green) (PDB ID 1WQ1)
Fig. 7 Model of the impact of phosphorylation on KRAS GTPase cycle and structural rationale. a Phosphorylation decouples KRAS from effectors and GTPase cycle regulation. The GTPase cycle of unmodified KRAS is shown on top. Nucleotide exchange and hydrolysis are accelerated by the activities of GEFs and GAPs, respectively. GTP-loaded KRAS binds and activates RAF. Src phosphorylation of Tyr32 and Tyr64 of KRAS-GDP or KRAS-GTP alters all steps in this GTPase cycle (lower part). Upon phosphorylation, KRAS becomes insensitive to regulation by both GEFs and GAPs, whereas intrinsic nucleotide exchange is enhanced and intrinsic GTP hydrolysis is impaired. This leads to the accumulation of phosphorylated KRAS-GTP, which has reduced affinity for RAF, thus phosphorylation limits KRAS signaling. SHP2 dephosphorylates KRAS and thereby unleashes KRAS-GTP to rapidly activate RAF. Inhibition of SHP2 promotes accumulation of phosphorylated KRAS, dampening RAF signaling and subsequently suppressing oncogenesis. Line thickness and number of arrowheads represent relative reaction rates of each step. b Ribbon diagram SOS (green) contact with Tyr32 and Tyr64 of RAS (PDB ID 1BKD). c Proposed coordination of switch I and switch II RAS residues in intrinsic GTP hydrolysis (PDB ID 4G0N). d Switch I and II (blue) of RAS are the main interaction site with GAP (green) (PDB ID 1WQ1)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 106

Metadata

Authors
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., Miao, J., Raught, B., Irwin, M. S., Lee, J. E., Yeh, J. J., Zhang, Z.-Y., Tsao, M.-S., Ikura, M., & Ohh, M.
Affiliations
  • University of Toronto (CA)
  • University Health Network (CA)
  • University of North Carolina at Chapel Hill (US)
  • Purdue University West Lafayette (US)
  • Hospital for Sick Children (CA)
Corresponding author
Ohh, Michael
Venue
Nature Communications
Published
2019-01-15
Volume
10
Issue
1
Pages
224-224
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2909726024
Cited by
103
References
68
Citations by year
2026: 12 · 2025: 8 · 2024: 16 · 2023: 14 · 2022: 20 · 2021: 13 · 2020: 14 · 2019: 6
FWCI
4.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UNC Libraries
Funders
  • Cancer Research Society
  • University of Toronto
  • National Institutes of Health (RO1 CA207288)
  • Canadian Institutes of Health Research (FDN‐1542284)
  • Canadian Cancer Society Research Institute (703209)
  • Japan Society for the Promotion of Science
  • National Cancer Institute (R01CA207288, R01CA199064)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords
KRAS, tyrosine phosphorylation, SHP2, Src kinase, oncogenic KRAS, SHP2 inhibitors, dark states, MAPK signaling
MeSH terms
Animals, Antineoplastic Agents, Humans, Male, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mice, SCID, GTP Phosphohydrolases, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, raf Kinases, Protein Tyrosine Phosphatase, Non-Receptor Type 11, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. https://app.cochat.ai/papers/10.1038/s41467-018-08115-8
The paper
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., Miao, J., Raught, B., Irwin, M. S., Lee, J. E., Yeh, J. J., Zhang, Z.-Y., Tsao, M.-S., Ikura, M., & Ohh, M. (2019). Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications. https://doi.org/10.1038/s41467-018-08115-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.